Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $9.09 billion. The enterprise value is $9.50 billion.
| Market Cap | 9.09B |
| Enterprise Value | 9.50B |
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Feb 14, 2025 |
Share Statistics
Bio-Techne has 158.09 million shares outstanding. The number of shares has decreased by -0.32% in one year.
| Current Share Class | 158.09M |
| Shares Outstanding | 158.09M |
| Shares Change (YoY) | -0.32% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 100.30% |
| Float | 156.27M |
Valuation Ratios
The trailing PE ratio is 58.55 and the forward PE ratio is 28.21. Bio-Techne's PEG ratio is 2.35.
| PE Ratio | 58.55 |
| Forward PE | 28.21 |
| PS Ratio | 7.76 |
| Forward PS | 7.13 |
| PB Ratio | 4.46 |
| P/TBV Ratio | 14.22 |
| P/FCF Ratio | 36.51 |
| P/OCF Ratio | 30.47 |
| PEG Ratio | 2.35 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.70, with an EV/FCF ratio of 37.37.
| EV / Earnings | 60.10 |
| EV / Sales | 7.94 |
| EV / EBITDA | 30.70 |
| EV / EBIT | 38.70 |
| EV / FCF | 37.37 |
Financial Position
The company has a current ratio of 3.94, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.94 |
| Quick Ratio | 2.45 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | 1.55 |
| Interest Coverage | 22.66 |
Financial Efficiency
Return on equity (ROE) is 7.82% and return on invested capital (ROIC) is 6.15%.
| Return on Equity (ROE) | 7.82% |
| Return on Assets (ROA) | 5.68% |
| Return on Invested Capital (ROIC) | 6.15% |
| Return on Capital Employed (ROCE) | 9.79% |
| Revenue Per Employee | $392,136 |
| Profits Per Employee | $51,837 |
| Employee Count | 3,050 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.19 |
Taxes
In the past 12 months, Bio-Techne has paid $27.66 million in taxes.
| Income Tax | 27.66M |
| Effective Tax Rate | 14.89% |
Stock Price Statistics
The stock price has decreased by -15.40% in the last 52 weeks. The beta is 1.29, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -15.40% |
| 50-Day Moving Average | 66.77 |
| 200-Day Moving Average | 72.42 |
| Relative Strength Index (RSI) | 36.56 |
| Average Volume (20 Days) | 1,991,598 |
Short Selling Information
The latest short interest is 6.27 million, so 3.96% of the outstanding shares have been sold short.
| Short Interest | 6.27M |
| Short Previous Month | 5.27M |
| Short % of Shares Out | 3.96% |
| Short % of Float | 4.01% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.20 billion and earned $158.10 million in profits. Earnings per share was $0.98.
| Revenue | 1.20B |
| Gross Profit | 792.00M |
| Operating Income | 245.55M |
| Pretax Income | 232.35M |
| Net Income | 158.10M |
| EBITDA | 309.53M |
| EBIT | 245.55M |
| Earnings Per Share (EPS) | $0.98 |
Balance Sheet
The company has $177.55 million in cash and $395.13 million in debt, giving a net cash position of -$217.58 million or -$1.38 per share.
| Cash & Cash Equivalents | 177.55M |
| Total Debt | 395.13M |
| Net Cash | -217.58M |
| Net Cash Per Share | -$1.38 |
| Equity (Book Value) | 2.08B |
| Book Value Per Share | 13.16 |
| Working Capital | 473.38M |
Cash Flow
In the last 12 months, operating cash flow was $304.72 million and capital expenditures -$50.41 million, giving a free cash flow of $254.30 million.
| Operating Cash Flow | 304.72M |
| Capital Expenditures | -50.41M |
| Free Cash Flow | 254.30M |
| FCF Per Share | $1.61 |
Margins
Gross margin is 66.22%, with operating and profit margins of 20.53% and 13.22%.
| Gross Margin | 66.22% |
| Operating Margin | 20.53% |
| Pretax Margin | 15.53% |
| Profit Margin | 13.22% |
| EBITDA Margin | 25.88% |
| EBIT Margin | 20.53% |
| FCF Margin | 21.26% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.56%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.56% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 32.66% |
| Buyback Yield | 0.32% |
| Shareholder Yield | 0.87% |
| Earnings Yield | 1.70% |
| FCF Yield | 2.74% |
Analyst Forecast
The average price target for Bio-Techne is $81.25, which is 41.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $81.25 |
| Price Target Difference | 41.24% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 10.76% |
| EPS Growth Forecast (5Y) | 27.51% |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 13.4 and a Piotroski F-Score of 5.
| Altman Z-Score | 13.4 |
| Piotroski F-Score | 5 |